Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Sanofi's strong fundamentals and core asset Dupixent are undervalued due to temporary vaccine market volatility and patent cliff anxieties. The manager bought...
— David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Sanofi
Market concerns over a potential vaccine critic heading the US HHS caused an industry-wide sell-off, which the manager believes is an overreaction for Sanofi given its vaccine division's small revenue share. The pipeline for...
Sanofi was a detractor this quarter.